ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals trades at a P/E of 19.65 with a market cap of $1.8B, positioning it at a moderate valuation relative to sector peers. The RSI of 44.3 signals neither overbought nor oversold conditions, suggesting the stock sits in neutral technical territory with room to move in either direction. What stands out is the elevated short interest at 19.44% of float—substantial enough to warrant attention given potential squeeze dynamics if positive catalysts emerge. The stock sits below its 52-week high, indicating it hasn't participated fully in any recent sector rallies. For a pharma company, this combination suggests a relatively quiet risk-reward setup without obvious technical extremes pulling valuations too far in either direction.